Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Adaptimmune Therapeutics

    NASDAQ: ADAP · Real-Time Price · USD
    0.28
    -0.00 (-1.06%)
    At close: Jun 09, 2025, 3:58 PM

    Adaptimmune Therapeutics Statistics

    Share Statistics

    Adaptimmune Therapeutics has 257.85M shares outstanding. The number of shares has increased by 501.05% in one year.

    Shares Outstanding

    n/a
    		 257.85M

    Shares Change (YoY)

    n/a
    		 501.05%

    Shares Change (QoQ)

    n/a
    		 500.14%

    Owned by Institutions (%)

    n/a
    		 8.11%

    Shares Floating

    n/a
    		 228.64M

    Failed to Deliver (FTD) Shares

    n/a
    		 440,479

    FTD / Avg. Volume

    n/a
    		 23.98%

    Short Selling Information

    The latest short interest is 5.83M, so 2.2% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.83M

    Short % of Shares Out

    n/a
    		 2.2%

    Short % of Float

    n/a
    		 2.67%

    Short Ratio (days to cover)

    n/a
    		 2.29

    Valuation Ratios

    The PE ratio is -1.92 and the forward PE ratio is -2.04. Adaptimmune Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -1.92

    Forward PE

    n/a
    		 -2.04

    PS Ratio

    n/a
    		 0.76

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 11.47

    P/FCF Ratio

    n/a
    		 -1.79

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Adaptimmune Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.92, with a Debt / Equity ratio of 6.26.

    Current Ratio

    n/a
    		 2.92

    Quick Ratio

    n/a
    		 2.8

    Debt / Equity

    n/a
    		 6.26

    Debt / EBITDA

    n/a
    		 -1.41

    Debt / FCF

    n/a
    		 -0.98

    Interest Coverage

    n/a
    		 -20.54

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $351,841.9

    Profits Per Employee

    n/a
    		 $-139,948.62

    Employee Count

    n/a
    		 506

    Asset Turnover

    n/a
    		 0.72

    Inventory Turnover

    n/a
    		 0.01

    Taxes

    Income Tax

    n/a
    		 3.58M

    Effective Tax Rate

    n/a
    		 -5.32%

    Stock Price Statistics

    The stock price has increased by -72.55% in the last 52 weeks. The beta is 2.25, so Adaptimmune Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.25

    52-Week Price Change

    n/a
    		 -72.55%

    50-Day Moving Average

    n/a
    		 0.27

    200-Day Moving Average

    n/a
    		 0.61

    Relative Strength Index (RSI)

    n/a
    		 50.01

    Average Volume (20 Days)

    n/a
    		 1,836,844

    Income Statement

    In the last 12 months, Adaptimmune Therapeutics had revenue of 178.03M and earned -70.81M in profits. Earnings per share was -0.28.

    Revenue

    n/a
    		 178.03M

    Gross Profit

    n/a
    		 177.96M

    Operating Income

    n/a
    		 -68.76M

    Net Income

    n/a
    		 -70.81M

    EBITDA

    n/a
    		 -52.66M

    EBIT

    n/a
    		 -63.89M

    Earnings Per Share (EPS)

    n/a
    		 -0.28
    Full Income Statement

    Balance Sheet

    The company has 91.14M in cash and 74.21M in debt, giving a net cash position of 16.93M.

    Cash & Cash Equivalents

    n/a
    		 91.14M

    Total Debt

    n/a
    		 74.21M

    Net Cash

    n/a
    		 16.93M

    Retained Earnings

    n/a
    		 -1.09B

    Total Assets

    n/a
    		 158.07M

    Working Capital

    n/a
    		 51.93M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -73.21M and capital expenditures -2.72M, giving a free cash flow of -75.93M.

    Operating Cash Flow

    n/a
    		 -73.21M

    Capital Expenditures

    n/a
    		 -2.72M

    Free Cash Flow

    n/a
    		 -75.93M

    FCF Per Share

    n/a
    		 -0.05
    Full Cash Flow Statement

    Margins

    Gross margin is 99.96%, with operating and profit margins of -38.62% and -39.78%.

    Gross Margin

    n/a
    		 99.96%

    Operating Margin

    n/a
    		 -38.62%

    Pretax Margin

    n/a
    		 -37.77%

    Profit Margin

    n/a
    		 -39.78%

    EBITDA Margin

    n/a
    		 -29.58%

    EBIT Margin

    n/a
    		 -38.62%

    FCF Margin

    n/a
    		 -42.65%

    Dividends & Yields

    ADAP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ADAP is $1.4, which is 400% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $1.4

    Price Target Difference

    n/a
    		 400%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -9.69

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist